Rising incidence of heart failure demands action

The Lancet

Volumn 391, Issue 10120, 2018, Pages 518-519

  Zannad, Faiez ^a,b  

^a UNIVERSITÉ DE LORRAINE   (France)

^b INI CRCT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ACUTE CORONARY SYNDROME; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ELECTRONIC HEALTH RECORD; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; NOTE; PREVALENCE; PRIORITY JOURNAL; SOCIOECONOMICS; RISK FACTOR;

HEART FAILURE; HUMANS; INCIDENCE; RISK FACTORS;

EID: 85034655425     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32873-8     Document Type: Note

References (12)

1. Conrad, N, Judge, A, Tran, J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet, 2017 published online Nov 21. http://dx.doi.org/10.1016/S0140-6736(17)32520-5.
2. Zannad, F, Pfeffer, MA, Bhatt, DL, et al. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart 103 (2017), 1156–1162.
3. Smolina, K, Wright, FL, Rayner, M, Goldacre, MJ, Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ, 344, 2012, d8059.
4. Chow, CK, Teo, KK, Rangarajan, S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 310 (2013), 959–968.
5. Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
6. Fitchett, D, Zinman, B, Wanner, C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 37 (2016), 1526–1534.
7. Leong, DP, Joseph, PG, McKee, M, et al. Reducing the global burden of cardiovascular disease, part 2. Circ Res 121 (2017), 695–710.
8. Packer, M, Who should deliver medical therapy for patients with chronic heart failure? An immediate call for action to implement a community-based collaborative solution. Circ Heart Fail, 10, 2017, e004332.
9. Farmakis, D, Stafylas, P, Giamouzis, G, Maniadakis, N, Parissis, J, The medical and socioeconomic burden of heart failure: a comparative delineation with cancer. Int J Cardiol 203:suppl C (2016), 279–281.
10. Fordyce, CB, Roe, MT, Ahmad, T, et al. Cardiovascular drug development: is it dead or just hibernating?. J Am Coll Cardiol 65 (2015), 1567–1582.
11. Herrett, E, Gallagher, AM, Bhaskaran, K, et al. Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 44 (2015), 827–836.
12. Ferreira, JP, Machu, JL, Girerd, N, et al. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail, 2017 published online Oct 7. DOI:10.1002/ehf2.12218.